Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Champions Oncology (CSBR) Revenue (2016 - 2026)

Champions Oncology has reported Revenue over the past 17 years, most recently at $16.6 million for Q1 2026.

  • For Q1 2026, Revenue fell 2.82% year-over-year to $16.6 million; the TTM value through Jan 2026 reached $57.9 million, down 1.1%, while the annual FY2025 figure was $56.9 million, 13.54% up from the prior year.
  • Revenue for Q1 2026 was $16.6 million at Champions Oncology, up from $15.0 million in the prior quarter.
  • Over five years, Revenue peaked at $17.0 million in Q1 2025 and troughed at $11.6 million in Q4 2023.
  • A 5-year average of $13.7 million and a median of $13.5 million in 2024 define the central range for Revenue.
  • Biggest five-year swings in Revenue: dropped 18.96% in 2023 and later skyrocketed 41.77% in 2025.
  • Year by year, Revenue stood at $14.3 million in 2022, then dropped by 18.96% to $11.6 million in 2023, then rose by 16.56% to $13.5 million in 2024, then grew by 11.46% to $15.0 million in 2025, then rose by 10.14% to $16.6 million in 2026.
  • Business Quant data shows Revenue for CSBR at $16.6 million in Q1 2026, $15.0 million in Q4 2025, and $14.0 million in Q3 2025.